# A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care

> **NCT02598011** · PHASE1 · WITHDRAWN · sponsor: **Tocagen Inc.**

## Conditions studied

- Newly Diagnosed High Grade Glioma (HGG)

## Interventions

- **BIOLOGICAL:** Toca 511
- **DRUG:** Toca FC

## Key facts

- **NCT ID:** NCT02598011
- **Lead sponsor:** Tocagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2022-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598011, "A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02598011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*